Rating Change
Piper Sandler analysts reiterated a Overweight rating on Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on July 31, 2026.
reiterateNASDAQ:KPTI
Piper Sandler Reiterates Overweight Rating on Karyopharm Therapeutics Inc. (KPTI)
Rating Change Piper Sandler analysts reiterated a Overweight rating on Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on July 31, 2026. Market Context Karyopharm Therapeutics Inc.
Market Context
Karyopharm Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $1.92 with a market capitalization of $59.5M.
Analyst coverage from Piper Sandler provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Karyopharm Therapeutics Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Karyopharm Therapeutics Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 31, 2026 | Piper Sandler | Overweight | N/A |
| Jul 31, 2026 | HC Wainwright & Co. | Neutral | N/A |
| May 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Apr 27, 2026 | Piper Sandler | Overweight | N/A |
| Mar 30, 2026 | Piper Sandler | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View KPTI Stock Page
Frequently Asked Questions
What does a Overweight rating mean for KPTI?
A Overweight rating from Piper Sandler reflects the analyst's outlook on Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KPTI forecast page.
